Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris

Introduction: Ranibizumab is a mouse monoclonal antibody fragment antigen-binding (Fab) against human vascular endothelial growth factor-A (VEGF-A), inhibiting angiogenesis. This antibody is commercially produced in Escherichia coli host and used to treat wet age-related macular degeneration (AMD).M...

Full description

Bibliographic Details
Main Authors: Shirin Movaghar Asareh, Tahereh Savei, Sareh Arjmand, Seyed Omid Ranaei Siadat, Fataneh Fatemi, Mehrab Pourmadadi, Javad Shabani Shayeh
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2022-05-01
Series:BioImpacts
Subjects:
Online Access:https://bi.tbzmed.ac.ir/PDF/bi-12-203.pdf
_version_ 1818200515746463744
author Shirin Movaghar Asareh
Tahereh Savei
Sareh Arjmand
Seyed Omid Ranaei Siadat
Fataneh Fatemi
Mehrab Pourmadadi
Javad Shabani Shayeh
author_facet Shirin Movaghar Asareh
Tahereh Savei
Sareh Arjmand
Seyed Omid Ranaei Siadat
Fataneh Fatemi
Mehrab Pourmadadi
Javad Shabani Shayeh
author_sort Shirin Movaghar Asareh
collection DOAJ
description Introduction: Ranibizumab is a mouse monoclonal antibody fragment antigen-binding (Fab) against human vascular endothelial growth factor-A (VEGF-A), inhibiting angiogenesis. This antibody is commercially produced in Escherichia coli host and used to treat wet age-related macular degeneration (AMD).Methods: In this study, the heavy and light chains of ranibizumab were expressed in Pichia pastoris. The expressed chains were incubated overnight at 4°C for interaction. The formation of an active structure was evaluated based on the interaction with substrate VEGF-A using an indirect ELISA, and an electrochemical setup. Furthermore, reconstruction of split enhanced green fluorescent protein (eGFP) reporter, chimerized at the C-terminus of the heavy and light chains, was used to characterize chains’ interaction. Results: P. pastoris efficiently expressed designed constructs and secreted them into the culture medium. The anti-Fab antibody detected the constructed Fab structure in western blot analysis. Reconstruction of the split reporter confirmed the interaction between heavy and light chains. The designed ELISA and electrochemical setup results verified the binding activity of the recombinant Fab structure against VEGF-A. Conclusion: In this work, we indicated that the heavy and light chains of ranibizumab Fab fragments (with or without linkage to split parts of eGFP protein) were produced in P. pastoris. The fluorescence of reconstructed eGFP was detected after incubating the equal ratio of chimeric-heavy and light chains. Immunoassay and electrochemical tests verified the bioactivity of constructed Fab. The data suggested that P. pastoris could be considered a potential efficient eukaryotic host for ranibizumab production.
first_indexed 2024-12-12T02:38:53Z
format Article
id doaj.art-7a8aee79e9ad46e8bf08c11481b44109
institution Directory Open Access Journal
issn 2228-5660
2228-5652
language English
last_indexed 2024-12-12T02:38:53Z
publishDate 2022-05-01
publisher Tabriz University of Medical Sciences
record_format Article
series BioImpacts
spelling doaj.art-7a8aee79e9ad46e8bf08c11481b441092022-12-22T00:41:13ZengTabriz University of Medical SciencesBioImpacts2228-56602228-56522022-05-0112320321010.34172/bi.2021.23219bi-23219Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastorisShirin Movaghar Asareh0Tahereh Savei1Sareh Arjmand2Seyed Omid Ranaei Siadat3Fataneh Fatemi4Mehrab Pourmadadi5Javad Shabani Shayeh6Protein Research Center, Shahid Beheshti University, Tehran, IranProtein Research Center, Shahid Beheshti University, Tehran, IranProtein Research Center, Shahid Beheshti University, Tehran, IranProtein Research Center, Shahid Beheshti University, Tehran, IranProtein Research Center, Shahid Beheshti University, Tehran, IranProtein Research Center, Shahid Beheshti University, Tehran, IranProtein Research Center, Shahid Beheshti University, Tehran, IranIntroduction: Ranibizumab is a mouse monoclonal antibody fragment antigen-binding (Fab) against human vascular endothelial growth factor-A (VEGF-A), inhibiting angiogenesis. This antibody is commercially produced in Escherichia coli host and used to treat wet age-related macular degeneration (AMD).Methods: In this study, the heavy and light chains of ranibizumab were expressed in Pichia pastoris. The expressed chains were incubated overnight at 4°C for interaction. The formation of an active structure was evaluated based on the interaction with substrate VEGF-A using an indirect ELISA, and an electrochemical setup. Furthermore, reconstruction of split enhanced green fluorescent protein (eGFP) reporter, chimerized at the C-terminus of the heavy and light chains, was used to characterize chains’ interaction. Results: P. pastoris efficiently expressed designed constructs and secreted them into the culture medium. The anti-Fab antibody detected the constructed Fab structure in western blot analysis. Reconstruction of the split reporter confirmed the interaction between heavy and light chains. The designed ELISA and electrochemical setup results verified the binding activity of the recombinant Fab structure against VEGF-A. Conclusion: In this work, we indicated that the heavy and light chains of ranibizumab Fab fragments (with or without linkage to split parts of eGFP protein) were produced in P. pastoris. The fluorescence of reconstructed eGFP was detected after incubating the equal ratio of chimeric-heavy and light chains. Immunoassay and electrochemical tests verified the bioactivity of constructed Fab. The data suggested that P. pastoris could be considered a potential efficient eukaryotic host for ranibizumab production.https://bi.tbzmed.ac.ir/PDF/bi-12-203.pdfranibizumabfab fragmentvegf-apichia pastorissplit reporteregfp
spellingShingle Shirin Movaghar Asareh
Tahereh Savei
Sareh Arjmand
Seyed Omid Ranaei Siadat
Fataneh Fatemi
Mehrab Pourmadadi
Javad Shabani Shayeh
Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
BioImpacts
ranibizumab
fab fragment
vegf-a
pichia pastoris
split reporter
egfp
title Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
title_full Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
title_fullStr Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
title_full_unstemmed Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
title_short Expression of functional eGFP-fused antigen-binding fragment of ranibizumab in Pichia pastoris
title_sort expression of functional egfp fused antigen binding fragment of ranibizumab in pichia pastoris
topic ranibizumab
fab fragment
vegf-a
pichia pastoris
split reporter
egfp
url https://bi.tbzmed.ac.ir/PDF/bi-12-203.pdf
work_keys_str_mv AT shirinmovagharasareh expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris
AT taherehsavei expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris
AT sareharjmand expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris
AT seyedomidranaeisiadat expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris
AT fatanehfatemi expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris
AT mehrabpourmadadi expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris
AT javadshabanishayeh expressionoffunctionalegfpfusedantigenbindingfragmentofranibizumabinpichiapastoris